Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells-Reference-Cited by-同舟云学术

Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells

Published:2020-05 Issue:4 Volume:525 Page:1074-1080
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Inoue Chisato^ORCID,Sobue Sayaka,Kawamoto Yoshiyuki,Nishizawa Yuji,Ichihara Masatoshi,Abe Akihiro,Hayakawa Fumihiko^ORCID,Suzuki Motoshi^ORCID,Nozawa Yoshinori,Murate Takahsi

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference36 articles.

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N. Engl. J. Med.,2001

2. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia;Balabanov;Drug Discov. Today Technol.,2014

3. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia;Soverini;Leuk. Res.,2014

4. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias;Cortes;N. Engl. J. Med.,2013

5. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia;Mathisen;Blood Rev.,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Collaborating single-cell and bulk RNA sequencing for comprehensive characterization of the intratumor heterogeneity and prognostic model development for bladder cancer;Aging;2023-11-06

2. Identification of antimycin A as a c-Myc degradation accelerator via high-throughput screening;Journal of Biological Chemistry;2023-09

3. SRSF1 promotes ASMC proliferation in asthma by competitively binding CCND2 with miRNA-135a;Pulmonary Pharmacology & Therapeutics;2022-12

4. Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies;Cells;2022-05-31

5. Targeting MCL-1 in cancer: current status and perspectives;Journal of Hematology & Oncology;2021-04-21